Harnessing Site- Selective Conjugation Platform AbClick® for Innovative Bioconjugate Therapies
- Introducing AbTis’ proprietary linker technologies to develop next-generation ADCs with enhanced stability, efficacy, and therapeutic potential, designed to optimize clinical outcomes
- Showcasing versatile and modular applicability of AbClick® for cost-effective, streamlined production of existing and novel bioconjugate modalities
- Exploring external innovation and opportunities for companies to leverage AbClick® to enhance their ADC pipeline development